All In Biotech

NDA 206756 · Boehringer Ingelheim

Stiolto Respimat

Olodaterol Hydrochloride, Tiotropium Bromide · Inhalation

Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

May 21, 2015

Approved uses

3

Original approval plus efficacy supplements

Registered trials

79

28 Phase 3, 0 recruiting

FAERS reports

5,135

1,966 serious, 373 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 30, 2025.

STIOLTO RESPIMAT is a combination of tiotropium bromide, an anticholinergic and olodaterol, a long-acting beta 2 -adrenergic agonist (LABA) indicated for the long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) Important limitations: STIOLTO RESPIMAT is NOT indicated to treat acute deterioration of COPD. ( 1.1 ) STIOLTO RESPIMAT is NOT indicated to treat asthma. ( 1.1 ) 1.1 Maintenance Treatment of COPD STIOLTO RESPIMAT is a combination of tiotropium bromide and olodaterol indicated for long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Important Limitations of Use STIOLTO RESPIMAT is not indicated to treat acute deteriorations of COPD [see Warnings and Precautions (5.2) ]. STIOLTO RESPIMAT is not indicated to treat asthma. The safety and effectiveness of STIOLTO RESPIMAT in asthma have not been established.

Mechanism: STIOLTO RESPIMAT STIOLTO RESPIMAT contains both tiotropium and olodaterol. The properties described below for the individual components apply to STIOLTO RESPIMAT. These drugs represent 2 different classes of medication (an anticholinergic and a beta-agonist) that have different effects on clinical and physiological indices. Tiotropium Tiotropium is a long-acting, muscarinic antagonist which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors, M 1 to M 5 . In the airways, it exhibits pharmacological effects through inhibition of M 3...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • STIOLTO RESPIMAT · OLODATEROL HYDROCHLORIDE EQ 0.0025MG BASE/INH; TIOTROPIUM BROMIDE EQ 0.0025MG BASE/INH · SPRAY, METERED, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Olodaterol" as an intervention, any sponsor and status, largest first.

All 79 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea934
  • cough422
  • drug ineffective345
  • off label use304
  • fatigue254
  • headache245
  • death230
  • diarrhoea219
  • pneumonia218
  • chronic obstructive pulmonary disease207
  • nausea193
  • dizziness192

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20141
2015185
2016423
2017539
2018479
2019428
2020480
2021434
2022424
2023408
2024444
2025473
2026417

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Stiolto Respimat (Tiotropium Br/Olodaterol HCl)

2024 spending

$449M

Beneficiaries

167,334

695,441 claims

Per beneficiary

$2,681

$113.32 per unit

View as table
YearSpending
2020$264,984,003
2021$345,628,078
2022$387,118,055
2023$432,253,137
2024$448,588,557

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 80 on PubMed

Sponsor: Boehringer Ingelheim

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.